http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-102017011629-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_13ac9f687154c95511646f3621605e02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-765 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D475-08 |
| filingDate | 2017-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42ae9a716ed76ffaab7804e897e9071c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82c5b3ce850df3755f2ba06e6982f4c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3acf7b3ce5c32308dcfe5b242c9fe769 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a97cdc050abe812dfe1bad46da5a43d |
| publicationDate | 2018-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-102017011629-A2 |
| titleOfInvention | nanomicelles formed from methotrexate-conjugated poloxamer and incorporated from etoposide for the treatment of retinoblastoma and other malignant tumors |
| abstract | nanomicelles formed from methotrexate - conjugated poloxamer and incorporated from etoposide for the treatment of retinoblastoma and other malignant tumors. The present invention relates to a pharmaceutical formulation composed of nanomicelles formed from methotrexate-conjugated poloxamer and incorporated by etoposide for the treatment of retinoblastoma and other malignant tumors. The aforementioned pharmaceutical formulation is composed of micellar nanometric systems formed by the methotrexate-conjugated poloxamer, which is positioned on the micellar surface, and incorporated with antitumor hydrophobic drugs, especially etoposide, present in the micellar hydrophobic nucleus. These nanomicels may be administered by the intraocular and / or parenteral routes. The formulation may be internalized by tumor cells expressing reduced folate and folate transporters due to the presence of methotrexate on the micellar surface. As a folic acid analogue, methotrexate acts as a recognition element for tumor cells. After cell uptake, methotrexate and etoposide are released to exert specific antitumor action. In addition, prolonged exposure of these drugs within the cell also ensures disruption of the cell cycle. poloxamer also exerts antiproliferative action. The proposed formulation further promotes antitumor effect specifically on tumor cells, which leads to the reduction of systemic side and / or toxic effects resulting from chemotherapy. In addition, it protects the incorporated etoposide from degradation processes due to ph variations and ensures its increased solubility in biological fluids, as well as that of other antineoplastic agents that have low aqueous solubility in the fluids. |
| priorityDate | 2017-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 315.